AR093532A1 - Compuestos y composiciones para el tratamiento de enfermedades parasitarias - Google Patents

Compuestos y composiciones para el tratamiento de enfermedades parasitarias

Info

Publication number
AR093532A1
AR093532A1 ARP130104250A ARP130104250A AR093532A1 AR 093532 A1 AR093532 A1 AR 093532A1 AR P130104250 A ARP130104250 A AR P130104250A AR P130104250 A ARP130104250 A AR P130104250A AR 093532 A1 AR093532 A1 AR 093532A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
halo
heteroaryl
independently selected
Prior art date
Application number
ARP130104250A
Other languages
English (en)
Spanish (es)
Inventor
Chatterjee Arnab
Nagle Advait
Paraselli Prasuna
Reddy Kondreddi Ravinder
Yong Leong Seh
Mishra Pranab
Moreau Robert
Thomas Roland Jason
Lin Sandra Sim Wei
Oliver Simon
Jocelyn Tan Liying
Ks Yeung Bryan
Zou Bin
Bollu Venkatataiah
Original Assignee
Irm Llc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc, Novartis Ag filed Critical Irm Llc
Publication of AR093532A1 publication Critical patent/AR093532A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP130104250A 2012-11-19 2013-11-19 Compuestos y composiciones para el tratamiento de enfermedades parasitarias AR093532A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728018P 2012-11-19 2012-11-19
US201361847860P 2013-07-18 2013-07-18

Publications (1)

Publication Number Publication Date
AR093532A1 true AR093532A1 (es) 2015-06-10

Family

ID=49667630

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104250A AR093532A1 (es) 2012-11-19 2013-11-19 Compuestos y composiciones para el tratamiento de enfermedades parasitarias

Country Status (19)

Country Link
US (3) US9556169B2 (cg-RX-API-DMAC7.html)
EP (1) EP2925757B1 (cg-RX-API-DMAC7.html)
JP (1) JP6298472B2 (cg-RX-API-DMAC7.html)
CN (1) CN105164124B (cg-RX-API-DMAC7.html)
AR (1) AR093532A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119727T1 (cg-RX-API-DMAC7.html)
DK (1) DK2925757T3 (cg-RX-API-DMAC7.html)
ES (1) ES2655030T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171998T1 (cg-RX-API-DMAC7.html)
HU (1) HUE037600T2 (cg-RX-API-DMAC7.html)
LT (1) LT2925757T (cg-RX-API-DMAC7.html)
ME (1) ME03042B (cg-RX-API-DMAC7.html)
PL (1) PL2925757T3 (cg-RX-API-DMAC7.html)
PT (1) PT2925757T (cg-RX-API-DMAC7.html)
RS (1) RS56720B1 (cg-RX-API-DMAC7.html)
SI (1) SI2925757T1 (cg-RX-API-DMAC7.html)
TW (1) TWI600654B (cg-RX-API-DMAC7.html)
UY (1) UY35146A (cg-RX-API-DMAC7.html)
WO (1) WO2014078802A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41338B1 (fr) * 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
EA201891672A1 (ru) 2016-01-21 2018-12-28 Новартис Аг Соединения и композиции для лечения криптоспоридиоза
TWI696615B (zh) * 2016-05-05 2020-06-21 瑞士商伊蘭科動物健康公司 雜芳基-1,2,4-三唑及雜芳基-三唑化合物
EP3484886B1 (en) * 2016-07-14 2020-03-04 Hoffmann-La Roche AG 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
EP3526220B1 (en) * 2016-10-13 2025-06-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Compounds and method for blocking transmission of malarial parasite
EP3609504A4 (en) 2017-03-01 2021-03-03 Anacor Pharmaceuticals, Inc. NEW OXABOROLE ANALOGUES AND USES OF THE LATEST
IL269390B (en) 2017-03-20 2022-08-01 Broad Inst Inc Compounds and methods for the treatment of parasitic diseases
US12018000B2 (en) 2017-03-27 2024-06-25 HYDRO-QUéBEC Lithium salts of cyano-substituted imidazole for lithium ion batteries
CN107037148B (zh) * 2017-04-07 2019-11-19 上海药明康德新药开发有限公司 卤泛曲林的高效液相检测方法
JOP20190278A1 (ar) 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
US11628593B2 (en) 2017-10-02 2023-04-18 Dal-Tile, Llc Method for manufacturing an engineered stone and an engineered stone
IL279977B2 (en) * 2018-07-09 2024-06-01 Boehringer Ingelheim Animal Health Usa Inc Heterocyclic anthelmintic compounds
GB201811695D0 (en) * 2018-07-17 2018-08-29 Salvensis Compounds for use in the treatment of fascioliasis
UY38540A (es) * 2019-01-14 2020-08-31 Pi Industries Ltd Compuestos de fenilamidina 3-sustituida, preparación y uso
JP7637630B2 (ja) 2019-03-19 2025-02-28 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 駆虫性アザベンゾチオフェンおよびアザベンゾフラン化合物
JP7693558B2 (ja) * 2019-06-07 2025-06-17 エランコ・ティアゲゾンタイト・アーゲー 内部寄生虫を治療するための二環式誘導体
RU2019123849A (ru) * 2019-07-29 2021-02-01 Дзе Брихэм Энд Уимен`З Хоспитал, Инк. Ингибиторы фактора ингибирования миграции макрофагов
CA3183100A1 (en) 2020-05-29 2021-12-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anthelmintic heterocyclic compounds
TW202229277A (zh) * 2020-10-14 2022-08-01 瑞士商諾華公司 用於治療隱孢子蟲病之化合物及組成物
WO2023275590A1 (en) 2021-06-29 2023-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Detection of phosphoinositides in blood cells as a biomarker for alpha synuclein associated pathologies and a method of treatment of parkinson's disease and the related neurodegenerations
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
KR20240112282A (ko) 2021-11-01 2024-07-18 베링거잉겔하임베트메디카게엠베하 구충제 피롤로피리다진 화합물
CA3181279A1 (en) * 2022-03-24 2023-09-24 Bloom Energy Corporation Fuel cell stack assembly including heat sink inserts
US12338188B2 (en) 2022-06-30 2025-06-24 Dal-Tile, Llc Method for manufacturing a decorative element comprising an engineered stone and a decorative element comprising an engineered stone
US12358305B2 (en) 2022-06-30 2025-07-15 Dal-Tile, Llc Method for manufacturing a decorative element comprising an engineered stone and a decorative element comprising an engineered stone
WO2024006974A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds
US20240124450A1 (en) 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
WO2024196989A1 (en) * 2023-03-20 2024-09-26 University Of Central Florida Research Foundation, Inc. Anti-malarial therapy
AR132354A1 (es) * 2023-04-13 2025-06-18 Syngenta Crop Protection Ag Derivados de pirazolo[1,5-a]piridina
EP4667535A1 (en) 2024-06-17 2025-12-24 SilOriX GmbH Nonlinear optical dyes with improved stability

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11505524A (ja) 1995-05-01 1999-05-21 藤沢薬品工業株式会社 イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途
DK0915880T3 (da) 1996-07-24 2008-02-11 Bristol Myers Squibb Pharma Co Azolotriaziner og pyrimidiner
EP0995742A4 (en) 1997-06-27 2004-08-25 Fujisawa Pharmaceutical Co SULPHONAMIDE COMPOUNDS AND THEIR MEDICAL USE
JP2001139575A (ja) 1999-11-15 2001-05-22 Fujisawa Pharmaceut Co Ltd 新規ピラゾロピリジン誘導体
GB0002336D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
GB0002312D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
EP1261607B1 (en) * 2000-03-01 2008-11-12 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
WO2001083479A2 (en) 2000-04-28 2001-11-08 Glaxo Group Limited Process for the preparation of pyrazolopyridine derivatives
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
ATE402164T1 (de) 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
AUPR916301A0 (en) 2001-11-29 2001-12-20 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
AU2003227437A1 (en) 2002-04-23 2003-11-10 Shionogi And Co., Ltd. PYRAZOLO(1,5-a)PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7365066B2 (en) 2002-09-17 2008-04-29 Eli Lilly And Company Pyrazolopyridine derivatives as pharmaceutical agents
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US7488745B2 (en) * 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
ES2349041T3 (es) 2004-07-16 2010-12-22 Schering Corporation Derivados de hidantoina para el tratamiento de trastornos inflamatorios.
AR050365A1 (es) 2004-08-02 2006-10-18 Osi Pharm Inc Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos.
CA2584248A1 (en) 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
CA2586259A1 (en) 2004-11-08 2006-05-11 Banyu Pharmaceutical Co., Ltd. Novel fused imidazole derivative
JP5132319B2 (ja) * 2004-12-21 2013-01-30 スミスクライン ビーチャム コーポレーション ２−ピリミジニルピラゾロピリジンＥｒｂＢキナーゼ阻害剤
US20080167314A1 (en) 2004-12-28 2008-07-10 Osamu Uchikawa Condensed Imidazole Compound And Use Thereof
US7713975B1 (en) 2005-01-12 2010-05-11 Alcon, Inc. 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
CA2620223A1 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2407459A1 (en) 2005-09-27 2012-01-18 Shionogi & Co., Ltd. Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity
EP1963320A1 (en) 2005-12-07 2008-09-03 OSI Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
RU2008127263A (ru) 2005-12-08 2010-01-20 Новартис АГ (CH) ПИРАЗОЛ [1,5-a] ПИРИДИН-3-КАРБОНОВЫЕ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ EphB-И VEGFR2-КИНАЗЫ
WO2007086080A2 (en) 2006-01-30 2007-08-02 Glenmark Pharmaceuticals Limited NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2009528289A (ja) 2006-02-27 2009-08-06 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
JP5352452B2 (ja) 2006-06-06 2013-11-27 メディシノバ， インコーポレイテッド 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法
DE102006029447A1 (de) 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
EP1873157A1 (en) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
AU2007292924A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
JP2010503383A (ja) 2006-09-12 2010-02-04 ザ ジェネラル ホスピタル コーポレイション 細胞シグナリングをモジュレートする化合物を同定するための方法およびこのような化合物を使用する方法
DE602007013441D1 (de) 2006-09-29 2011-05-05 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
MX2009004700A (es) 2006-11-06 2009-05-15 Supergen Inc Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
WO2008072682A1 (ja) 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ［１，２－ｂ］ピリダジン誘導体
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
MX2009006706A (es) 2006-12-22 2009-07-02 Astex Therapeutics Ltd Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
CA2676138A1 (en) 2007-01-26 2008-08-07 Irm Llc Compounds and compositions as kinase inhibitors
WO2008156783A2 (en) 2007-06-18 2008-12-24 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities
WO2009008748A1 (en) 2007-07-11 2009-01-15 Auckland Uniservices Limited Pyrazolo[1,5-a]pyridines and their use in cancer therapy
US20100292236A1 (en) 2007-07-19 2010-11-18 H. Lundbeck A/S 5-Membered Heterocyclic Amides And Related Compounds
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2717034A1 (en) 2008-02-28 2009-09-03 Pascal Furet Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
US8507501B2 (en) 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
ES2548135T3 (es) 2008-05-13 2015-10-14 Novartis Ag Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa
JP2009298710A (ja) 2008-06-11 2009-12-24 Daiichi Sankyo Co Ltd イミダゾ［１，２−ｂ］ピリダジン誘導体含有医薬組成物
KR20180018839A (ko) 2008-06-30 2018-02-21 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 분화
WO2010017047A1 (en) 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
US8518911B2 (en) 2008-08-05 2013-08-27 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyridines as MARK inhibitors
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2010034738A2 (en) 2008-09-24 2010-04-01 Basf Se Pyrazole compounds for controlling invertebrate pests
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
DK2376490T3 (da) 2008-12-04 2013-04-15 Proximagen Ltd Imidazopyridinforbindelser
WO2010074586A1 (en) 2008-12-23 2010-07-01 Pathway Therapeutics Limited Pyrazolo[1,5-a]pyridine and imidazo[1,2-a]pyridine derivatives and their use in cancer therapy
CA2750935A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
AU2010226490A1 (en) 2009-03-20 2011-10-06 Amgen Inc. Inhibitors of PI3 kinase
WO2010108187A2 (en) 2009-03-20 2010-09-23 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
WO2010117787A2 (en) 2009-03-30 2010-10-14 The Brigham And Women's Hospital, Inc. Inhibiting eph b-3 kinase
WO2010118207A1 (en) 2009-04-09 2010-10-14 Schering Corporation Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
AR077463A1 (es) * 2009-07-09 2011-08-31 Irm Llc Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
RU2421455C2 (ru) 2009-07-14 2011-06-20 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" СПОСОБ ПОЛУЧЕНИЯ МЕТИЛ 7-АРИЛКАРБАМОИЛ-6-БЕНЗОИЛ-2-МЕТИЛ-3-ФЕНИЛПИРАЗОЛО[1,5-a]ПИРИМИДИН-5-КАРБОКСИЛАТОВ
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
US8865726B2 (en) 2009-09-03 2014-10-21 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
WO2011038097A2 (en) 2009-09-23 2011-03-31 Amira Pharmaceuticals, Inc. Indolizine inhibitors of 5-lipoxygenase
GB201002911D0 (en) 2010-02-19 2010-04-07 Medical Res Council Compound
US20150291598A1 (en) 2012-11-19 2015-10-15 Novartis Ag Compounds and compositions for the treatment of parasitic diseases

Also Published As

Publication number Publication date
US9556169B2 (en) 2017-01-31
ME03042B (me) 2018-10-20
CY1119727T1 (el) 2018-06-27
JP2016505529A (ja) 2016-02-25
LT2925757T (lt) 2017-12-27
HRP20171998T1 (hr) 2018-02-09
JP6298472B2 (ja) 2018-03-20
PT2925757T (pt) 2018-01-09
UY35146A (es) 2014-06-30
US20180230145A1 (en) 2018-08-16
RS56720B1 (sr) 2018-03-30
ES2655030T3 (es) 2018-02-16
EP2925757A1 (en) 2015-10-07
EP2925757B1 (en) 2017-10-04
HUE037600T2 (hu) 2018-09-28
TWI600654B (zh) 2017-10-01
TW201429967A (zh) 2014-08-01
US20160333012A1 (en) 2016-11-17
US9926314B2 (en) 2018-03-27
WO2014078802A1 (en) 2014-05-22
CN105164124A (zh) 2015-12-16
DK2925757T3 (en) 2018-01-15
US20150344471A1 (en) 2015-12-03
SI2925757T1 (en) 2018-01-31
CN105164124B (zh) 2017-03-15
PL2925757T3 (pl) 2018-06-29

Similar Documents

Publication Publication Date Title
AR093532A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CO2019008531A2 (es) Análogos de atazanavir (atv) para tratar infecciones por vih.
AR091093A1 (es) Tienopirimidinas
AR090847A1 (es) Compuestos moduladores del receptor huerfano retinoideo (ror)
AR091628A1 (es) 7h-pirrolo[2,3-d]pirimidinas 4-(amino-substituidas) como inhibidores de lrrk2
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR106865A1 (es) Piridinas sustituidas y métodos de uso
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
CO2017003070A2 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MY180666A (en) Substituted pyrazolo [3,4-b] pyridines as medicaments
CO6771446A2 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
AR090292A1 (es) Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
AR087913A1 (es) Inhibidores sustituidos de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2,2,1]heptan-3-carboxamida de catepsina c
AR088810A1 (es) Moduladores del receptor mas acoplado a la proteina g utiles en el tratamiento de trastornos cardiovasculares y composiciones farmaceuticas que los contienen
EA201391558A1 (ru) Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения
EA201401082A1 (ru) Фармацевтические препараты, содержащие антагонисты ccr3
AR087868A1 (es) Compuestos de triazolopiridina como moduladores de la tirosina quinasa c-met
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR099160A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios
AR084731A1 (es) Derivados de imidazoquinolina sustituidos

Legal Events

Date Code Title Description
FB Suspension of granting procedure